全文获取类型
收费全文 | 24422篇 |
免费 | 2171篇 |
国内免费 | 65篇 |
专业分类
耳鼻咽喉 | 247篇 |
儿科学 | 923篇 |
妇产科学 | 828篇 |
基础医学 | 2977篇 |
口腔科学 | 311篇 |
临床医学 | 3215篇 |
内科学 | 4449篇 |
皮肤病学 | 531篇 |
神经病学 | 2378篇 |
特种医学 | 483篇 |
外科学 | 2559篇 |
综合类 | 250篇 |
一般理论 | 37篇 |
预防医学 | 3644篇 |
眼科学 | 303篇 |
药学 | 1527篇 |
中国医学 | 21篇 |
肿瘤学 | 1975篇 |
出版年
2023年 | 330篇 |
2022年 | 190篇 |
2021年 | 798篇 |
2020年 | 583篇 |
2019年 | 876篇 |
2018年 | 917篇 |
2017年 | 699篇 |
2016年 | 764篇 |
2015年 | 796篇 |
2014年 | 1089篇 |
2013年 | 1588篇 |
2012年 | 2141篇 |
2011年 | 2249篇 |
2010年 | 1247篇 |
2009年 | 1180篇 |
2008年 | 1667篇 |
2007年 | 1749篇 |
2006年 | 1600篇 |
2005年 | 1365篇 |
2004年 | 1197篇 |
2003年 | 1059篇 |
2002年 | 954篇 |
2001年 | 164篇 |
2000年 | 105篇 |
1999年 | 126篇 |
1998年 | 179篇 |
1997年 | 115篇 |
1996年 | 78篇 |
1995年 | 91篇 |
1994年 | 76篇 |
1993年 | 51篇 |
1992年 | 51篇 |
1991年 | 51篇 |
1990年 | 48篇 |
1989年 | 40篇 |
1988年 | 41篇 |
1987年 | 48篇 |
1986年 | 53篇 |
1985年 | 31篇 |
1984年 | 40篇 |
1983年 | 23篇 |
1982年 | 32篇 |
1981年 | 19篇 |
1980年 | 20篇 |
1979年 | 24篇 |
1978年 | 9篇 |
1977年 | 10篇 |
1974年 | 17篇 |
1973年 | 10篇 |
1971年 | 9篇 |
排序方式: 共有10000条查询结果,搜索用时 17 毫秒
71.
72.
73.
Amy E. Chadwick 《Health communication》2016,31(6):782-785
Climate change is one of the most serious and pervasive challenges facing us today. Our changing climate has implications not only for the ecosystems upon which we depend, but also for human health. Health communication scholars are well-positioned to aid in the mitigation of and response to climate change and its health effects. To help theorists, researchers, and practitioners engage in these efforts, this primer explains relevant issues and vocabulary associated with climate change and its impacts on health. First, this primer provides an overview of climate change, its causes and consequences, and its impacts on health. Then, the primer describes ways to decrease impacts and identifies roles for health communication scholars in efforts to address climate change and its health effects. 相似文献
74.
75.
Emma Morton Erin E. Michalak Anthony Levitt Robert D. Levitan Amy Cheung Rachel Morehouse Rajamannar Ramasubbu Lakshmi N. Yatham Edwin M. Tam Raymond W. Lam 《Revue canadienne de psychiatrie》2021,66(3):289
Objective:Bright light therapy is increasingly recommended (alone or in combination with antidepressant medication) to treat symptoms of nonseasonal major depressive disorder (MDD). However, little is known about its impacts on quality of life (QoL), a holistic, patient-valued outcome.Methods:This study utilizes secondary outcome data from an 8-week randomized, controlled, double blind trial comparing light monotherapy (n = 32), fluoxetine monotherapy (n = 30), and the combination of these (n = 27) to placebo (n = 30). QoL was assessed using the Quality of Life Enjoyment and Satisfaction Questionnaire Short Form (Q-LES-Q-SF). Treatment-related differences in QoL improvements were assessed using a repeated measures analysis of variance. The influence of potential predictors of QoL (demographic variables and change in depressive symptoms) were investigated via hierarchical linear regression.Results:Q-LES-Q-SF scores significantly improved across all treatment conditions; however, no significant differences were observed between treatment arms. QoL remained poor relative to community norms by the end of the trial period: Across conditions, 70.6% of participants had significantly impaired QoL at the 8-week assessment. Reduction in depressive scores was a significant predictor of improved QoL, with the final model accounting for 54% of variance in QoL change scores.Conclusion:The findings of this study emphasize that improvement in QoL and reduction in depressive symptoms in MDD, while related, cannot be taken to be synonymous. Adjunctive therapies may be required to address unmet QoL needs in patients with MDD receiving antidepressant or light therapies. Further research is required to explore additional predictors of QoL in order to better refine treatments for MDD. 相似文献
76.
77.
Kathryn Beabout Troy G. Hammerstrom Anisha Maria Perez Bárbara Freitas Magalh?es Amy G. Prater Thomas P. Clements Cesar A. Arias Gerda Saxer Yousif Shamoo 《Antimicrobial agents and chemotherapy》2015,59(9):5561-5566
Tigecycline is a translational inhibitor with efficacy against a wide range of pathogens. Using experimental evolution, we adapted Acinetobacter baumannii, Enterococcus faecium, Escherichia coli, and Staphylococcus aureus to growth in elevated tigecycline concentrations. At the end of adaptation, 35 out of 47 replicate populations had clones with a mutation in rpsJ, the gene that encodes the ribosomal S10 protein. To validate the role of mutations in rpsJ in conferring tigecycline resistance, we showed that mutation of rpsJ alone in Enterococcus faecalis was sufficient to increase the tigecycline MIC to the clinical breakpoint of 0.5 μg/ml. Importantly, we also report the first identification of rpsJ mutations associated with decreased tigecycline susceptibility in A. baumannii, E. coli, and S. aureus. The identified S10 mutations across both Gram-positive and -negative species cluster in the vertex of an extended loop that is located near the tigecycline-binding pocket within the 16S rRNA. These data indicate that S10 is a general target of tigecycline adaptation and a relevant marker for detecting reduced susceptibility in both Gram-positive and -negative pathogens. 相似文献
78.
79.
80.